India, May 18 -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company, reported financial results for the first quarter of 2026 and provided updates for its investigational candidates.
Company Profile
Compugen uses Unigen, its AI/ML-powered computational discovery platform, to identify novel drug targets and develop therapeutics in cancer immunotherapies. Compugen's innovative immuno-oncology pipeline comprises four clinical-stage programs, namely COM701, COM902, Rilvegostomig, and GS-0321 (previously COM503). And Rilvegostomig and GS-0321 are partnered programs
Compugen is currently conducting a blinded randomised ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum...